505 related articles for article (PubMed ID: 8598700)
21. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
22. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
[TBL] [Abstract][Full Text] [Related]
23. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Argiris A; Seropian S; Cooper DL
Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
[TBL] [Abstract][Full Text] [Related]
25. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
26. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
27. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
Lickliter JD; Begley CG; Boyd AW; Szer J; Grigg AP
Leuk Lymphoma; 1994 Sep; 15(1-2):91-7. PubMed ID: 7532059
[TBL] [Abstract][Full Text] [Related]
28. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
Dreger P; Marquardt P; Haferlach T; Jacobs S; Mülverstedt T; Eckstein V; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
Br J Cancer; 1993 Nov; 68(5):950-7. PubMed ID: 7692921
[TBL] [Abstract][Full Text] [Related]
29. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
Grigg A; Begley CG; Juttner CA; Szer J; To LB; Maher D; McGrath KM; Morstyn G; Fox RM; Sheridan WP
Bone Marrow Transplant; 1993; 11 Suppl 2():23-9. PubMed ID: 8334435
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
31. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
[TBL] [Abstract][Full Text] [Related]
32. Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
Tendas A; Cupelli L; Bruno A; Niscola P; De Angelis V; Datturi T; Cantoni F; De Meis I; Dentamaro T; de Fabritiis P
Blood Transfus; 2012 Oct; 10(4):561-2. PubMed ID: 22395357
[No Abstract] [Full Text] [Related]
33. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Salloum E; Jillella AP; Nadkarni R; Seropian S; Hu GL; D'Andrea E; Zelterman D; Cooper DL
Cancer; 1998 Apr; 82(8):1506-12. PubMed ID: 9554528
[TBL] [Abstract][Full Text] [Related]
34. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
35. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
Sheridan WP; Begley CG; Juttner CA; Szer J; To LB; Maher D; McGrath KM; Morstyn G; Fox RM
Lancet; 1992 Mar; 339(8794):640-4. PubMed ID: 1371817
[TBL] [Abstract][Full Text] [Related]
36. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
[TBL] [Abstract][Full Text] [Related]
37. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial.
Szer J; Curtis DJ; Bardy PG; Grigg AP
Aust N Z J Med; 1999 Aug; 29(4):487-93. PubMed ID: 10868525
[TBL] [Abstract][Full Text] [Related]
38. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Vellenga E; van Agthoven M; Croockewit AJ; Verdonck LF; Wijermans PJ; van Oers MH; Volkers CP; van Imhoff GW; Kingma T; Uyl-de Groot CA; Fibbe WE
Br J Haematol; 2001 Aug; 114(2):319-26. PubMed ID: 11529850
[TBL] [Abstract][Full Text] [Related]
39. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Martín A; Pérez-Simón JA; Caballero MD; López-Holgado N; Vázquez L; del Cañizo MC; San Miguel JF
Haematologica; 2005 Jan; 90(1):78-85. PubMed ID: 15642673
[TBL] [Abstract][Full Text] [Related]
40. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
